Skip to main content

Plexiform Neurofibroma clinical trials at UC Davis

1 research study open to eligible people

Showing trials for
  • Join A Study of an Experimental New Drug for Neurofibromatosis

    open to eligible people ages 2 years and up

    This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901).

    Sacramento, California and other locations

Last updated: